Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea

Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?

(2016) Alpo Vuorio et al.   EUROPEAN HEART JOURNAL

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

(2016) John J.P. Kastelein et al.   EUROPEAN HEART JOURNAL

Statin Initiation During Childhood in Patients With Familial Hypercholesterolemia

(2016) Marjet J.A.M. Braamskamp et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PCSK9 inhibition: the way forward in the treatment of dyslipidemia

(2015) Robert M. Stoekenbroek et al.   BMC Medicine

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

(2015) John J.P. Kastelein et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

(2015) Albert Wiegman et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study

(2015) Marjet J.A.M. Braamskamp et al.   Journal of Clinical Lipidology

Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood

(2015) Gisle Langslet et al.   Journal of Clinical Lipidology

Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk

(2015) Marjet J.A.M. Braamskamp et al.   JOURNAL OF PEDIATRICS

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence

(2015) Marjet J. A. M. Braamskamp et al.   PEDIATRIC DRUGS

Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials

(2015) C. Li et al.   Journal of the American Heart Association

Markers of atherosclerotic development in children with familial hypercholesterolemia: A literature review

(2014) Ingunn Narverud et al.   ATHEROSCLEROSIS

Ten-Year Follow-up After Initiation of Statin Therapy in Children With Familial Hypercholesterolemia

(2014) D. Meeike Kusters et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Mortality Among Patients With Familial Hypercholesterolemia: A Registry‐Based Study in Norway, 1992–2010

(2014) Liv Mundal et al.   Journal of the American Heart Association

Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades

(2013) Avishay Elis et al.   CARDIOLOGY IN THE YOUNG

Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia

(2013) Dorothé M. Kusters et al.   CIRCULATION RESEARCH

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing

(2008) Brian Starr et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

(2008) A. Neil et al.   EUROPEAN HEART JOURNAL